Fosun Pharma Invites Chinese and Foreign Experts to Jointly Discuss Prevention and Control Measures of COVID-19 Epidemic in Africa

05-19 2020

(29 April 2020, Shanghai) In order to support African medical institutions in their response to the COVID-19 pandemic, Fosun Pharma, partnering with Shanghai Fosun Foundation, Fosu...

World Malaria Day 2020 | Eliminating Malaria & Preventing COVID-19, Zero Malaria Starts with Me

04-26 2020

(April 25 2020, Shanghai) On World Malaria Day 2020, countries across the world are trying to contain the spread of COVID-19 pandemic. At the same time, African countries are facin...

Fosun Pharma Announces 2019 Annual Results

03-30 2020

（31 March, 2020, Shanghai）March 30 2020, Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK), a leading healthcare group in China, anno...

Fosun Kite’s Axicabtagene Ciloleucel Granted Priority Review by China NMPA

03-17 2020

Summary: Fosun Kite’s autologous CD19-directed CAR-T cell therapy Axicabtagene Ciloleucel has been granted priority review status by China NMPA

Fosun Pharma and BioNTech form COVID-19 vaccine strategic alliance in China

03-16 2020

Fosun Pharma has been licensed by BioNTech to exclusively develop and commercialize COVID-19 vaccines based on its mRNA technology platform in China Fosun Pharma will commercializ...

Fosun Pharma Receives NMPA Approval to Initiate Phase III Clinical Trial for its Tenapanor Tables

03-13 2020

（12 March, 2020, Shanghai）Recently, Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) announced that its subsidiary Fosun Pharma Indu...